ARA-290 (cibinetide) is an 11–amino acid peptide engineered from erythropoietin’s helix-B that selectively activates the EPOR–CD131 ‘innate repair receptor’ to…
Half-life
Short (~20 minutes after SC; minutes after IV), with pharmacodynamic effects outlasting plasma exposure
Delivery
Subcutaneous injection (e.g., once daily in 28-day study designs); IV used in early PK work.
Suggested dosage
Not specified
Usage
Mechanism of action
Benefits (5)
- Reduces neuropathic pain and autonomic symptoms in SFN studies
- Improves quality-of-life measures
- Increases corneal small-fiber nerve density in clinical imaging
- Anti-inflammatory, cytoprotective effects without erythropoiesis
- Metabolic improvements noted in type 2 diabetes cohorts
Side effects (3)
- Generally well tolerated in trials
- Mild injection-site reactions
- No meaningful changes in hematocrit/hemoglobin (non-erythropoietic)